Cargando…
Cost-effectiveness of breast, lung, colon, prostate and cervical cancer outcomes in Brazil: a worldwide comparison
INTRODUCTION: Cancer is the second leading cause of death in the world, and it is expected to be the main cause by the year 2030. Current trends of higher incidence and the introduction of new treatments lead to the challenge of treating more people with increasing costs per capita. In Brazil, curre...
Autores principales: | Pellegrini, Rodrigo, Reinert, Tomás, Barrios, Carlos Henrique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241450/ https://www.ncbi.nlm.nih.gov/pubmed/34267799 http://dx.doi.org/10.3332/ecancer.2021.1243 |
Ejemplares similares
-
Lack of access to CDK4/6 inhibitors for premenopausal patients with metastatic breast cancer in Brazil: estimation of the number of premature deaths
por: Reinert, Tomás, et al.
Publicado: (2020) -
Estimation of the Number of Brazilian Women Living With Metastatic Breast Cancer
por: Reinert, Tomás, et al.
Publicado: (2020) -
Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab
por: Barrios, Carlos Henrique, et al.
Publicado: (2019) -
Disparities in Breast, Lung, and Cervical Cancer Trials Worldwide
por: Ramaswami, Ramya, et al.
Publicado: (2018) -
Association of ESR1 Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil
por: Reinert, Tomás, et al.
Publicado: (2019)